Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
about
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy?Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer.Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection.The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.Detection of circulating tumor cells in pulmonary venous blood for resectable non-small cell lung cancer.Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma.Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.
P2860
Q33886353-730933F0-F082-4CC4-A675-5A1241A4A1D7Q35078470-9A5D23F2-A4CD-4F07-9D95-A9EB5DBA9BF4Q35106153-1C3A4784-07A6-4FDD-B08A-1A0837816C94Q36063291-BFBDA285-5007-4CCF-944B-EFCD216921EDQ36525431-613A2BAA-1FC9-4B34-8DD6-FA2E35C574DEQ36731328-464D4880-A201-478B-A4B1-72FA4C6AD5B9Q36815636-34F354DF-650D-4CA7-B975-40F83ABDEC5FQ37121347-0B49C982-269A-4DF1-AC89-ECEDD278609DQ40405752-F1310CFF-DF62-4965-B1E3-DE6ACE343FB3Q44300864-F1827EBE-532C-494E-A536-D1AE1D4F7B3DQ46090770-DE3267FD-B624-4204-A1A2-A4D2D4829700Q49232721-8BE0DE18-7792-497B-926A-EE50C86A86F5Q49418567-F2FBBDE0-6E59-4E21-8CF0-6F90903DE4B8Q52723563-73D449B1-4B5A-4B2D-A3EA-C323E9A29E52Q55329630-A4B7AA06-506A-4ED1-A9A0-08519AEA2A51Q55630135-75B1F4BE-DE1D-4465-8D92-DAD6FD6A500F
P2860
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@ast
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@en
type
label
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@ast
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@en
prefLabel
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@ast
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@en
P2093
P2860
P50
P1476
Computed tomography RECIST ass ...... fter neoadjuvant chemotherapy.
@en
P2093
Apar Pataer
Arlene M Correa
David C Rice
Edward S Kim
J Jack Lee
Jeremy J Erasmus
Kathryn A Gold
Neda Kalhor
Stephen G Swisher
University of Texas M.D. Anderson Lung Cancer Collaborative Research Group
P2860
P304
P356
10.1097/JTO.0B013E3182774108
P577
2013-02-01T00:00:00Z